HighVista Strategies’s Inhibrx INBX Stock Holding History

HighVista Strategies’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,626	Closed	-$257K	–	164
2025 Q3	$257K	Buy	+7,626	New	+$188K	0.06%	144

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies's INBX Position: Q4 2025 in Review

HighVista Strategies sold out of Inhibrx (INBX) in Q4 2025, closing a stake of 7,626 shares — an estimated $257K sold.

HighVista Strategies first reported a position in INBX in Q3 2025 and held it in 1 quarter. The position peaked at $257K in Q3 2025. 138 funds tracked by Wall St. Rank hold INBX as of Q4 2025.

HighVista Strategies reported no remaining Inhibrx position as of Q4 2025 after selling out during the quarter.
HighVista Strategies sold 7,626 Inhibrx shares in Q4 2025, an estimated $257K.
HighVista Strategies first reported a position in Inhibrx in Q3 2025 and held it in 1 quarter.
HighVista Strategies's Inhibrx position peaked at $257K in Q3 2025.
138 funds tracked by Wall St. Rank held Inhibrx as of Q4 2025.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.